IMMX Live signals | Maximize Profits with Getagraph.com

BUY 118278 min ago

@ $3.23

Issued: 9 Feb 2024 @ 14:14

Return: -32.71%

Previous signal: Feb 8 - 10:29

Previous signal: Sell

Return: 1.20 %

Live Chart Being Loaded With Signals

Commentary (1 May 2024 @ 16:00):

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia...

Stats
Today's Volume	55 706.00
Average Volume	253 827
Market Cap	57.28M
EPS	$-0.255 ( 2024-04-01 )
Next earnings date	( $-0.230 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.44
ATR14	$0.0110 (0.51%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-11	Hsu Jason	Buy	31 000	Common Stock
2023-12-08	Hsu Jason	Buy	25 000	Common Stock
2023-08-14	Morris Gabriel S	Buy	293 000	Stock Options
2023-08-14	Rachman Ilya M	Buy	293 000	Stock Options
2023-09-15	Hsu Jason	Buy	7 000	Common Stock

INSIDER POWER
99.99
Last 65 transactions
Buy: 7 237 723 \| Sell: 879 400

Volume Correlation

Long: 0.28 (neutral)

Short: -0.77 (moderate negative)

Signal:(49.478) Neutral

Immix Biopharma, Inc. Correlation

10 Most Positive Correlations
MOMO	0.931
NYMTP	0.93
TOUR	0.928
QFIN	0.924
WB	0.921
OM	0.917
MLCO	0.917
GGAL	0.917
VBNK	0.915
TELA	0.91

10 Most Negative Correlations
SWAV	-0.921
NVTSW	-0.914
USCB	-0.913
THTX	-0.904
LARK	-0.903
PCRX	-0.899
SNPX	-0.894
PIII	-0.894
GOSS	-0.894
BCAB	-0.892

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Immix Biopharma, Inc. Correlation - Currency/Commodity

0.85
( strong )

0.67
( moderate )

0.85
( strong )

0.76
( moderate )

-0.70
( moderate negative )

Immix Biopharma, Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-5 468.00 (0.00 %)
EPS:	$-0.890

FY	2023
Revenue:	$0
Gross Profit:	$-5 468.00 (0.00 %)
EPS:	$-0.890

FY	2022
Revenue:	$-89.52M
Gross Profit:	$-89.52M (100.00 %)
EPS:	$-0.620

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-2 907.85

Financial Reports:

No articles found.

Immix Biopharma, Inc.

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.